<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Aoti, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/aoti-inc</link>
    <description>Latest news and press releases for Aoti, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 06:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/aoti-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e07b78dffbe2df126068.webp</url>
      <title>Aoti, Inc.</title>
      <link>https://6ix.com/company/aoti-inc</link>
    </image>
    <item>
      <title>Real-world study of AOTI’s TWO2® therapy</title>
      <link>https://6ix.com/company/aoti-inc/news/real-world-study-of-aotis-two2r-therapy</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/real-world-study-of-aotis-two2r-therapy</guid>
      <pubDate>Mon, 27 Apr 2026 06:00:00 GMT</pubDate>
      <description>AOTI, Inc. announced positive results from a large, 3,126-patient study published in the Journal of Vascular Surgery-Vascular Insights, demonstrating that its Topical Wound Oxygen (TWO2) therapy achieved a 64.8% complete healing rate for chronic lower extremity wounds, with only a 2.7% recurrence rate over a mean follow-up of 13.9 months. The therapy also significantly reduced hospitalizations to 3.7% and amputations to 6.1% in this high-risk patient population, which had failed to heal with oth</description>
    </item>
    <item>
      <title>Grant of awards under Long Term Incentive Plan</title>
      <link>https://6ix.com/company/aoti-inc/news/grant-of-awards-under-long-term-incentive-plan-6</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/grant-of-awards-under-long-term-incentive-plan-6</guid>
      <pubDate>Thu, 23 Apr 2026 06:00:00 GMT</pubDate>
      <description>AOTI, Inc. announced that on April 22, 2026, performance share awards were granted under its Long Term Incentive Plan to its CEO, CFO, and COO. The CEO received 678,471 awards, the CFO received 377,099 awards, and the COO received 270,672 awards, all with an exercise price of £0.37. These awards will vest in three years, contingent upon achieving specific Adjusted EBITDA and Adjusted EBITDA margin performance conditions measured over a three-year period ending December 31, 2028.
                </description>
    </item>
    <item>
      <title>2025 Annual Report and Notice of AGM</title>
      <link>https://6ix.com/company/aoti-inc/news/2025-annual-report-and-notice-of-agm-5</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/2025-annual-report-and-notice-of-agm-5</guid>
      <pubDate>Tue, 21 Apr 2026 06:00:00 GMT</pubDate>
      <description>AOTI, Inc. has announced that its 2025 Annual Report and Financial Statements, along with the 2026 Notice of Annual General Meeting, will be available on its website shortly, with documents being posted around April 22, 2026. The Annual General Meeting is scheduled for May 21, 2026, at 10:00 am BST in London. Shareholders are encouraged to vote by proxy, and details regarding the AGM arrangements are outlined in the Notice.
                Disclaimer*</description>
    </item>
    <item>
      <title>Director/PDMR Shareholding</title>
      <link>https://6ix.com/company/aoti-inc/news/directorpdmr-shareholding-959</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/directorpdmr-shareholding-959</guid>
      <pubDate>Thu, 02 Apr 2026 16:17:00 GMT</pubDate>
      <description>AOTI Inc. announced that on April 1, 2026, Non-executive Chairman Douglas Lefort and his spouse received a distribution of 971,367 common shares from their consulting vehicle, Wolfpack Consulting Limited, through its liquidation. This transaction did not alter their total beneficial holding, which remains at 1,451,621 common shares, representing approximately 1.36% of the company&apos;s issued share capital. The distribution involved 679,957 shares to Mr. Lefort and 291,410 shares to Mrs. Lefort, wit</description>
    </item>
    <item>
      <title>Final Results</title>
      <link>https://6ix.com/company/aoti-inc/news/final-results-625</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/final-results-625</guid>
      <pubDate>Mon, 30 Mar 2026 06:00:00 GMT</pubDate>
      <description>AOTI, Inc. reported 2025 results with revenue growth of 14.0% to $66.5 million, driven by a 37.6% increase in Medicaid revenue to $29.6 million, primarily from New York, despite US healthcare market disruptions. Adjusted EBITDA decreased by 6.4% to $7.5 million due to investments in market access and non-cash provisions, resulting in an adjusted EBITDA margin of 11.3%. The company&apos;s net debt stands at $6.5 million, a shift from net cash in the prior year, reflecting a drawdown from its loan faci</description>
    </item>
    <item>
      <title>Full Year Trading Update and Notice of Results</title>
      <link>https://6ix.com/company/aoti-inc/news/full-year-trading-update-and-notice-of-results-17</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/full-year-trading-update-and-notice-of-results-17</guid>
      <pubDate>Mon, 23 Feb 2026 07:00:00 GMT</pubDate>
      <description>AOTI, Inc. reported full-year 2025 revenue of approximately $66.5 million, a 14% increase from the prior year, and expects results to be in line with consensus, though net debt rose to $6.5 million due to increased receivables, particularly in Arizona where Medicaid reimbursement issues persist, leading the company to cease treating new Arizona Medicaid patients from April 1, 2026. Despite these headwinds, the company implemented organizational changes, anticipates a near-term CMS local coverage</description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/aoti-inc/news/holdings-in-company-1055</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/holdings-in-company-1055</guid>
      <pubDate>Mon, 15 Dec 2025 10:17:00 GMT</pubDate>
      <description>Wasatch Advisors LP has reduced its holding in AOTI Inc. to 12.23% of shares outstanding, down from a previous notification of 13.677%. This change, which occurred on December 12, 2025, represents an acquisition or disposal of shares, with the total number of shares outstanding held by Wasatch Advisors LP now at 13,006,869.
                Disclaimer*</description>
    </item>
    <item>
      <title>Appointment of Joint Corporate Broker</title>
      <link>https://6ix.com/company/aoti-inc/news/appointment-of-joint-corporate-broker-152</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/appointment-of-joint-corporate-broker-152</guid>
      <pubDate>Mon, 06 Oct 2025 06:00:00 GMT</pubDate>
      <description>AOTI, INC. announced the appointment of Panmure Liberum Limited as Joint Corporate Broker, effective October 6, 2025. Panmure Liberum will work alongside Peel Hunt LLP, the company&apos;s existing Nominated Adviser and corporate broker. The medical technology group focuses on durable healing of wounds and prevention of amputations.

                Disclaimer*</description>
    </item>
    <item>
      <title>2025 Interim Results</title>
      <link>https://6ix.com/company/aoti-inc/news/2025-interim-results-16</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/2025-interim-results-16</guid>
      <pubDate>Mon, 22 Sep 2025 06:00:00 GMT</pubDate>
      <description>AOTI, Inc. reported interim results for the six months ended June 30, 2025, with revenues increasing by 20.9% to $31.8 million compared to $26.3 million in H1 2024, driven mainly by a 57.1% increase in Medicaid revenue. Adjusted EBITDA decreased by 9.5% to $3.1 million, compared to $3.4 million in the prior year. The company reported a net debt position of $5.4 million, a shift from a net cash position of $5.5 million in H1 2024, due to an additional $11.0 million loan. They also amended the cov</description>
    </item>
    <item>
      <title>Notice of Results</title>
      <link>https://6ix.com/company/aoti-inc/news/notice-of-results-367</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/notice-of-results-367</guid>
      <pubDate>Mon, 08 Sep 2025 06:00:00 GMT</pubDate>
      <description>AOTI, INC. will release its interim results for the six months ended 30 June 2025, on Monday 22 September 2025. An analyst meeting will be held at 09:30 British Summer Time on the same day. Additionally, a presentation for existing and potential shareholders will be held via the Investor Meet Company platform at 11:30 BST, also on Monday 22 September. Questions for the investor presentation can be submitted until 09:00 BST on 21 September.

                Disclaimer*</description>
    </item>
    <item>
      <title>NICE fast track recommendation for Topical Oxygen</title>
      <link>https://6ix.com/company/aoti-inc/news/nice-fast-track-recommendation-for-topical-oxygen</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/nice-fast-track-recommendation-for-topical-oxygen</guid>
      <pubDate>Wed, 03 Sep 2025 06:00:00 GMT</pubDate>
      <description>AOTI, INC. announced that topical oxygen therapy is now included in the updated NICE guidelines as an adjunct to standard care for diabetic foot ulcers not responding to treatment. The company&apos;s Topical Wound Oxygen (TWO2) therapy is also active on the NHS Supply Chain&apos;s Advanced Wound Care Framework, facilitating accelerated marketing in the UK. An estimated 1% of the £192bn NHS budget is consumed by the diabetic foot epidemic this year. The NICE fast-track treatment recommendation is not expec</description>
    </item>
    <item>
      <title>Results of Placing</title>
      <link>https://6ix.com/company/aoti-inc/news/results-of-placing-73</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/results-of-placing-73</guid>
      <pubDate>Thu, 31 Jul 2025 06:00:00 GMT</pubDate>
      <description>Results of Placing.</description>
    </item>
    <item>
      <title>Proposed Placing in AOTI Inc.</title>
      <link>https://6ix.com/company/aoti-inc/news/proposed-placing-in-aoti-inc</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/proposed-placing-in-aoti-inc</guid>
      <pubDate>Wed, 30 Jul 2025 15:36:00 GMT</pubDate>
      <description>Proposed Placing in AOTI Inc..</description>
    </item>
    <item>
      <title>California Medicaid Provider ID Awarded</title>
      <link>https://6ix.com/company/aoti-inc/news/california-medicaid-provider-id-awarded</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/california-medicaid-provider-id-awarded</guid>
      <pubDate>Mon, 21 Jul 2025 06:00:00 GMT</pubDate>
      <description>California Medicaid Provider ID Awarded.</description>
    </item>
    <item>
      <title>Result of AGM</title>
      <link>https://6ix.com/company/aoti-inc/news/result-of-agm-962</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/result-of-agm-962</guid>
      <pubDate>Wed, 25 Jun 2025 12:24:00 GMT</pubDate>
      <description>Result of AGM.</description>
    </item>
    <item>
      <title>AOTI unlocks broad market access in Germany</title>
      <link>https://6ix.com/company/aoti-inc/news/aoti-unlocks-broad-market-access-in-germany</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/aoti-unlocks-broad-market-access-in-germany</guid>
      <pubDate>Mon, 23 Jun 2025 06:00:00 GMT</pubDate>
      <description>AOTI unlocks broad market access in Germany.</description>
    </item>
    <item>
      <title>End of Distribution Compliance Period</title>
      <link>https://6ix.com/company/aoti-inc/news/end-of-distribution-compliance-period</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/end-of-distribution-compliance-period</guid>
      <pubDate>Wed, 18 Jun 2025 06:00:00 GMT</pubDate>
      <description>End of Distribution Compliance Period.</description>
    </item>
    <item>
      <title>2024 Annual Report and Notice of AGM</title>
      <link>https://6ix.com/company/aoti-inc/news/2024-annual-report-and-notice-of-agm-4</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/2024-annual-report-and-notice-of-agm-4</guid>
      <pubDate>Tue, 27 May 2025 06:00:00 GMT</pubDate>
      <description>2024 Annual Report and Notice of AGM.</description>
    </item>
    <item>
      <title>Presentation at AJ Bell and Shares Spotlight Event</title>
      <link>https://6ix.com/company/aoti-inc/news/presentation-at-aj-bell-and-shares-spotlight-event</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/presentation-at-aj-bell-and-shares-spotlight-event</guid>
      <pubDate>Mon, 19 May 2025 06:00:00 GMT</pubDate>
      <description>Presentation at AJ Bell and Shares Spotlight Event.</description>
    </item>
    <item>
      <title>Director Shareholding - Share Purchase</title>
      <link>https://6ix.com/company/aoti-inc/news/director-shareholding-share-purchase</link>
      <guid isPermaLink="true">https://6ix.com/company/aoti-inc/news/director-shareholding-share-purchase</guid>
      <pubDate>Tue, 13 May 2025 06:00:00 GMT</pubDate>
      <description>Director Shareholding - Share Purchase.</description>
    </item>
  </channel>
</rss>